Haemophilus b conjugate vaccine(GSK Plc)(Haemophilus b conjugate vaccine(GSK Plc)) - 在研适应症：嗜血杆菌感染_专利_临床

概要

基本信息

药物类型

预防性疫苗、类毒素疫苗、结合疫苗

别名

Hib vaccine conjugate(GSK Plc)、Hiberix

靶点-

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段批准上市

首次获批日期

美国 (2009-08-19),

嗜血杆菌感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

19

项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床试验

NCT03893448 / Completed临床3期

A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants. The primary hypotheses are that: 1) V114 is non-inferior to Prevnar 13™ for the 13 shared serotypes between V114 and Prevnar 13™ based on response rates at 30 days following Dose 3; 2) V114 is non-inferior to Prevnar 13™ for the 2 unique V114 serotypes based on the response rate of the 2 unique V114 serotypes compared with the lowest response rate of any of the shared serotypes in Prevnar 13™, excluding serotype 3, at 30 days following Dose 3; 3) V114 is non-inferior to Prevnar 13™ for the 13 shared serotypes based on anti-pneumococcal polysaccharide (PnPs) serotype-specific immunoglobulin g (IgG) geometric mean concentrations (GMCs) at 30 days following Dose 3; 4) V114 is non-inferior to Prevnar 13™ for the 2 unique V114 serotypes based on the anti-PnPs serotype-specific IgG GMCs of the 2 unique V114 serotypes compared with the lowest IgG GMC of any of the shared serotypes in Prevnar 13™, excluding serotype 3, at 30 days following Dose 3; 5) V114 is non-inferior to Prevnar 13™ for the 13 shared serotypes between V114 and Prevnar 13™ based on anti-PnPs serotype-specific IgG GMCs at 30 days following Dose 4; and 6) V114 is non-inferior to Prevnar 13™ for the 2 unique V114 serotypes based on anti-PnPs serotype-specific IgG GMCs of the 2 unique V114 serotypes compared with the lowest IgG GMC of any of the shared serotypes in Prevnar 13, excluding serotype 3, at 30 days following Dose 4.

开始日期2019-06-19

申办/合作机构

Merck Sharp & Dohme Corp.

NCT03620162 / Completed临床3期

A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

The goal of this study is to evaluate the safety, tolerability, and immunogenicity of the Pneumococcal Conjugate Vaccines (PCVs) V114 and Prevnar 13™ in healthy infants switched from Prevnar 13™ to V114 during the four-dose PCV immunization schedule.

开始日期2018-10-18

申办/合作机构

Merck Sharp & Dohme Corp.

NCT03621670 / Active, not recruiting临床3期

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccines(RIV).

开始日期2018-07-27

申办/合作机构

GSK Plc

100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床结果

登录后查看更多信息

100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的转化医学

登录后查看更多信息

100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的专利（医药）

登录后查看更多信息

70

项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的文献（医药）

2019-03-01·Vaccine3区 · 医学

Impact of the introduction of the Haemophilus influenzae type b conjugate vaccine in an urban setting in southern India

3区 · 医学

Article

作者: Santosham, Mathuram ; Nedunchelian, Krishnamoorthy ; Suresh, Saradha ; Fitzwater, Sean Patrick ; Ramachandran, Padmanabhan ; Chandran, Aruna ; Kahn, Geoffrey D

INTRODUCTIONHaemophilus influenzae type b was the leading cause of bacterial meningitis in infants and children below the age of two years prior to the introduction of H. influenzae type b conjugate vaccines. In December 2011, the Indian government introduced H. influenzae b vaccine in the state of Tamilnadu. A prospective surveillance for bacterial meningitis was established at the Institute of Child Health in Chennai to evaluate the etiology of meningitis and impact of the vaccine.MATERIAL AND METHODSInfants aged one to 23 months who were admitted to the hospital with symptoms of suspected bacterial meningitis were enrolled and lumbar puncture was performed. Cerebrospinal fluid samples were analyzed for white blood cells, protein, and glucose. Bacterial culture and a latex agglutination test for common bacterial pathogens were performed.RESULTSBetween January 2009 and March 2014, 4,770 children with suspected bacterial meningitis were enrolled. Prior to the introduction of the vaccine, an average of 11.7 cases of H. influenzae b meningitis and 31.1 cases of probable meningitis with no etiology were identified each year. After introduction, the number of cases were reduced by 79% and 44% respectively. The average H. influenzae b vaccine coverage after introduction was 69% among all children with clinically suspected meningitis. In contrast, the mean number of aseptic meningitis and pneumococcal meningitis cases remained stable throughout the pre and post vaccination period; 28.2 and 4.8 per year, respectively.CONCLUSIONSH. influenzae b conjugate vaccine reduced the number of cases of H. influenzae b meningitis and probable meningitis within the first two years of its introduction. The impact against meningitis was higher than the vaccination rate, indicating indirect effects of the vaccine. India has recently scaled up the use of Hib conjugate vaccine throughout the country which should substantially reduce childhood meningitis rates further in the country.

2018-05-04·Human Vaccines & Immunotherapeutics3区 · 医学

Progress toward the global control ofNeisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

3区 · 医学

Review

作者: Rouphael, N. G. ; Stephens, D. S. ; Dretler, A. W.

The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global implementation. Meningococcal protein-polysaccharide conjugate vaccines to serogroups A, C, W, and Y (modeled after the Haemophilus influenzae b conjugate vaccines) provide better duration of protection and immunologic memory, and overcome weak immune responses in infants and young children and hypo-responsive to repeated vaccine doses seen with polysaccharide vaccines. ACWY conjugate vaccines also interfere with transmission and reduce nasopharyngeal colonization, thus resulting in significant herd protection. Advances in serogroup B vaccine development have also occurred using conserved outer membrane proteins with or without OMV as vaccine targets. Challenges for meningococcal vaccine research remain including developing combination vaccines containing ACYW(X) and B, determining the ideal booster schedules for the conjugate and MenB vaccines, and addressing issues of waning effectiveness.

2017-10-01·Pediatric Infectious Disease Journal4区 · 医学

Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study

4区 · 医学

Article

作者: Sutherland, Megan R. ; Lebel, Marc H. ; Ben Jmaa, Wissal ; Cloutier, Anik ; Martin, Brigitte ; Hernández, Alfredo I. ; Nuyt, Anne Monique ; Lachance, Christian ; Pladys, Patrick ; Germain, Nathalie

Background:Inflammation may depress respiration in neonates. This study aimed to establish a link between postimmunization inflammation and cardio-respiratory events (CREs).Methods:Randomized double-blind controlled study of infants born < 32 weeks gestation receiving the 2 months vaccine, which comprised diphtheria and tetanus toxoids and acellular pertussis adsorbed combined with inactivated poliomyelitis vaccines and Haemophilus b conjugate and the pneumococcal conjugate 10-valent vaccines. Infants were randomized to ibuprofen treatment or a placebo group (n = 28/group). C-reactive protein (CRP) and prostaglandins E2 (PgE2) levels were assessed before and after immunization. CREs were recorded for 72 hours. Heart rate variability was assessed by polysomnography.Results:In the placebo group, immunization was associated with significantly increased CRP levels and an increase in CRE (8.6 ± 11.1 before versus 14.0 ± 12.8 after), which did not reach statistical significance (P = 0.08), and no change in PgE2. The increase in CRP was correlated with changes in CRE (r = 0.4: P < 0.05). In the ibuprofen group, immunization significantly increased CRP levels but was not associated with change in CRE (6.7 ± 7.7 before versus 6.8 ± 9.7 after) and PgE2 levels. Comparing the groups, variation in CRE (ΔCRE before versus after immunization) was significantly lower in the ibuprofen group (0.1 ± 7.9 versus 5.4 ± 10.0 ΔCRE; P < 0.05).Conclusion:The first immunization of infants born < 32 weeks was associated with an increase in CRP. Ibuprofen treatment significantly attenuated the variation (Δ) in CRE following first immunization in these infants but the current study could not demonstrate an impact on CRP and PgE2 levels. The impact of anti-inflammatory treatment on antigenicity must be evaluated before their clinical use aiming at reducing CRE after immunization in preterm infants.

1

项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的新闻（医药）

2024-03-12

·生物制品圈

2024年美国免疫实践咨询委员会≥19岁成人疫苗推荐免疫程序

2023年10月，美国免疫实践咨询委员会（ACIP）批准了2024年美国≥19岁成人疫苗推荐免疫程序。该程序每年发布一次，以整合和总结ACIP关于成人疫苗接种建议的更新，并协助医疗保健提供者实施当前的ACIP建议。ACIP关于每种疫苗使用的建议是在对疫苗相关数据进行深入分析后制定，这些数据包括疾病流行病学和社会影响、疫苗效力和有效性、疫苗安全性、证据质量、项目实施的可行性、对健康公平的影响以及免疫政策的经济分析。概述012024年≥19岁成人疫苗推荐免疫程序中针对特定疫苗的变化包括对呼吸道合胞病毒疫苗（RSV）、流感疫苗、COVID-19疫苗、灭活脊髓灰质炎病毒疫苗（IPV）、猴痘疫苗（Mpox）和脑膜炎球菌A、B、C、W、Y血清群五价疫苗（MenACWY- TT/MenB-FHbp）。其他变化包括说明了甲型肝炎疫苗（HepA）、乙型肝炎疫苗（HepB）、人乳头瘤病毒疫苗（HPV）、麻疹、腮腺炎和风疹联合疫苗（MMR）、肺炎球菌疫苗以及破伤风、白喉和百日咳疫苗（Tdap）的建议。01表1.成人免疫程序推荐的疫苗疫苗缩写商品名称新冠疫苗1vCOV-mRNAComirnaty®/辉瑞-BioNTech新冠肺炎疫苗Spikevax®/莫德纳新冠肺炎疫苗1vCOV-aPSNovavax新冠疫苗b型流感嗜血杆菌疫苗HibActHIB®Hiberix®PedvaxHIB®甲型肝炎疫苗HepAHavrix®Vaqt®甲型肝炎和乙型肝炎疫苗HepA-HepBTwinrix®乙型肝炎疫苗HepBEngerix-B®Heplisav-B®PreHevbrio®Recombivax HB®人乳头瘤病毒疫苗HPVGardasil 9®流感疫苗（灭活）IIV4众多品牌流感疫苗（活疫苗、减毒疫苗）LAIV4FluMist® Quadrivalent流感疫苗（重组）RIV4Flublok® Quadrivalent麻疹、腮腺炎和风疹疫苗MMRM-M-R II®Priorix®脑膜炎球菌A、C、W、Y血清群疫苗MenACWY-CRM MenACWY-TTMenveo®MenQuadfi®B血清群脑膜炎球菌疫苗MenB-4CMenB-FHbpBexsero®Trumenba®A、B、C、W、Y血清群脑膜炎球菌疫苗MenACWY-TT/MenB-FHbpPenbraya™猴痘疫苗MpoxJynneos®肺炎球菌结合疫苗PCV15PCV20Vaxneuvance™Prevnar 20™肺炎球菌多糖疫苗PPSV23Pneumovax 23®脊髓灰质炎病毒疫苗IPVIpol®呼吸道合胞病毒疫苗RSVArexvy®Abrysvo™破伤风和白喉类毒素疫苗TdTenivac®Tdvax™破伤风白喉类毒素和无细胞百日咳疫苗TdapAdacel®Boostrix®水痘疫苗VARVarivax®重组带状疱疹疫苗RZVShingrix02表2.2024年美国按年龄组分列的推荐成人免疫接种时间表03 表3.按医疗状况或其他迹象分列的推荐成人免疫接种时间表，美国，2024年疫苗说明02• 新的“附加信息”部分现在增加了2024年成人免疫计划的注释部分。• COVID-19：现在建议所有成年人至少接种1剂更新的（2023-2024年组分）COVID-19疫苗。所需的剂次数和剂次间隔可能因患者既往疫苗接种史、免疫功能低下状态和使用的疫苗产品而异。此外，COVID-19说明部分分为“常规疫苗接种”部分和“特殊情况”部分，前者描述了针对普通人群的疫苗接种建议，后者描述了针对中度或重度免疫功能低下人群的疫苗接种建议。• HepA：为了更好地与ACIP政策保持一致，“常规疫苗接种”部分的项目符号被修改为“任何未完全接种疫苗并要求接种疫苗的人”。• HepB：在“常规疫苗接种”部分，在描述针对≥60岁人群的基于风险的疫苗接种建议的项目符号中添加了额外的背景和细节。此外，在“常规疫苗接种”部分的末尾增加了一个注释，描述了对≥60岁糖尿病患者的共同临床决策建议。• HPV：在“常规疫苗接种”部分，删除了关于未按免疫程序完成接种的指南。当使用推荐的接种间隔完成全程HPV疫苗接种后，不建议额外剂次。• 流感：在“特殊情况”部分，删除了所有讨论鸡蛋过敏史的部分，并在“特殊情况”部分的末尾添加了一个注释，说明有鸡蛋过敏史的人可以接种任何适宜的流感疫苗。最后，删除了描述吉兰-巴雷综合征的部分。• MMR：对“常规疫苗接种”部分进行了细微更改，以提高语言清晰度。• 脑膜炎球菌：添加了资源链接，以帮助医疗保健提供者共享MenB疫苗接种的临床决策建议。有关使用新许可的五价脑膜炎球菌疫苗（Penbraya）的信息在脑膜炎球菌注释部分的末尾提供。• 猴痘：猴痘疫苗接种是成人疫苗推荐免疫程序注释部分的新内容。列出了需要常规接种Jynneos疫苗的危险因素。有关在医疗保健提供者和孕妇中使用Jynneos的要点在Mpox注释部分的末尾提供。• 肺炎球菌：在“常规疫苗接种”和“特殊情况”部分进行了细微编辑，以明确肺炎球菌疫苗的指导和最低间隔。• 脊髓灰质炎病毒：在“常规疫苗接种”部分添加了其他背景信息。本节现在呼吁未接种疫苗或未完全接种疫苗的成年人完成3剂IPV基础免疫。增加了一份声明，指出大多数在美国出生和长大的成年人可以假设他们小时候接种了脊髓灰质炎疫苗。“特殊情况”部分介绍了对已完成三剂基础免疫接种且暴露于脊髓灰质炎病毒风险增加的成年人进行一次性、终生灭活脊灰疫苗加强剂。• 呼吸道合胞病毒：今年增加了一个新的呼吸道合胞病毒注释部分。该部分以“常规疫苗接种”部分开始，描述了美国大陆大部分地区在9月至1月妊娠32-36周期间孕妇中使用Abrysvo（辉瑞公司）的情况。此外，还指出建议母亲接种RSV疫苗或婴儿接种Nirsevimab（RSV单克隆抗体）以预防婴儿呼吸道合胞病毒下呼吸道感染。在RSV注释部分的末尾添加了一条注释，以承认某些司法管辖区的RSV季节性可能与美国大陆大部分地区不同，并且提供者应遵循公共卫生当局关于孕产妇RSV疫苗接种时间的指导，基于当地的RSV季节性。 “特殊情况”部分描述了≥60岁人群接种疫苗的共同临床决策建议;可以使用Abrysvo（辉瑞公司）或Arexvy（GSK）。此外，还添加了一个资源链接，以帮助医疗保健提供者共享RSV疫苗接种的临床决策建议。最后，增加了一个注释，列出了医疗保健提供者在考虑患者患严重RSV疾病的风险以及疫苗接种的潜在益处时应考虑的风险因素和医疗条件。• Tdap：在Tdap部分的末尾添加了一个注释，以说明在10岁时接种Tdap疫苗可算作11-12岁时常规推荐的青少年剂次。参考文献：Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:11–15. DOI：http://dx.doi.org/10.15585/mmwr.mm7301a3识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗临床研究

100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AG51	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
嗜血杆菌感染	美国	GlaxoSmithKline LLC	2009-08-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
百日咳	临床1期	菲律宾	GSK Plc	2005-06-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03893448 (PNEU-PED \| V114-029, CTgov)	临床3期	肺炎球菌感染 \| 肺炎 \| 18型肌张力障碍	1,720	HIBERIX™+Pentacel™+Varivax™+RECOMBIVAX HB™+VAQTA™+RotaTeq™+V114+MMR II™ (V114)	鹹製鏇遞齋蓋鬱鬱積夢(構鹹壓顧觸繭網繭鏇選) = 衊鹹遞簾艱衊簾鏇醖齋醖獵憲鹹淵構鬱衊糧簾 (憲繭衊鏇蓋構衊願壓艱, 齋觸廠餘鏇鹹選壓廠鑰 ~ 構鹹糧夢壓積鑰積襯餘) 更多	-	2022-03-25
				HIBERIX™+Pentacel™+Varivax™+RECOMBIVAX HB™+VAQTA™+RotaTeq™+Prevnar 13™+MMR II™ (Prevnar 13™)	鹹製鏇遞齋蓋鬱鬱積夢(構鹹壓顧觸繭網繭鏇選) = 顧醖夢蓋觸壓憲齋範壓醖獵憲鹹淵構鬱衊糧簾 (憲繭衊鏇蓋構衊願壓艱, 觸願願窪窪壓構鏇鑰餘 ~ 獵糧糧範糧窪鬱膚蓋衊) 更多
NCT03620162 (V114-027, CTgov)	临床3期	肺炎球菌感染	900	HIBERIX™+Pentacel™+VARIVAX™+RECOMBIVAX HB™+RotaTeq™+Prevnar 13™+M-M-R™ II (Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™)	鹽壓觸齋觸顧願遞鏇選(壓獵醖構蓋齋鑰夢壓構) = 鏇餘醖構選衊鬱獵範衊艱齋繭範積繭網蓋選憲 (憲願齋觸鑰繭餘鏇齋衊, 醖積獵窪觸選鹽夢膚鹹 ~ 醖遞築鑰衊願繭餘範願) 更多	-	2021-08-23
				HIBERIX™+Pentacel™+VARIVAX™+RECOMBIVAX HB™+RotaTeq™+Prevnar 13™+V114+M-M-R™ II (Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114)	鹽壓觸齋觸顧願遞鏇選(壓獵醖構蓋齋鑰夢壓構) = 憲繭蓋窪選襯夢蓋鹽構艱齋繭範積繭網蓋選憲 (憲願齋觸鑰繭餘鏇齋衊, 網蓋願夢繭簾窪顧鹽艱 ~ 製糧鬱憲膚鏇齋齋廠衊) 更多
NCT03207750 (CTgov)	临床3期	轮状病毒感染 \| 轮状病毒引起的病毒性胃肠炎	1,280	human rotavirus (HRV) vaccine+Hiberix+Prevnar-13+Pediarix (HRV Porcine Circovirus (PCV)-Free Liquid Group)	鹹糧顧獵選積壓簾獵築(憲廠窪衊觸壓鏇衊遞鹽) = 製製齋鑰醖鏇積簾膚製齋夢鏇膚壓繭網願遞鏇 (製襯艱憲鬱願鑰繭壓餘, 夢鹽夢窪壓齋窪蓋壓範 ~ 醖窪觸構構齋觸蓋廠壓) 更多	-	2019-10-31
				human rotavirus (HRV) vaccine+Hiberix+Prevnar-13+Pediarix (HRV Lyophilized Group)	鹹糧顧獵選積壓簾獵築(憲廠窪衊觸壓鏇衊遞鹽) = 糧夢遞窪廠簾繭構淵淵齋夢鏇膚壓繭網願遞鏇 (製襯艱憲鬱願鑰繭壓餘, 鏇廠構遞窪衊糧壓醖淵 ~ 壓鬱顧壓憲膚廠鏇選製) 更多
NCT00547248 (CTgov)	临床3期	链球菌感染	756	Synflorix+Tritanrix-HepB+Hiberix+Polio Sabin (Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group)	(憲範觸壓蓋餘積築簾網) = 積願齋餘壓築憲獵鑰觸顧膚範選構製齋網繭遞 (衊願獵醖夢鑰襯範獵壓, 衊願鑰顧獵淵衊壓窪築 ~ 網網鹽淵廠艱鏇築襯顧) 更多	-	2019-01-14
				Tritanrix-HepB+Hiberix+Polio Sabin+Prevenar (Wyeth) (Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group)	(憲範觸壓蓋餘積築簾網) = 遞網艱襯積積構膚醖簾顧膚範選構製齋網繭遞 (衊願獵醖夢鑰襯範獵壓, 夢壓構遞獵鏇構襯網顧 ~ 壓蓋膚憲糧窪壓築憲衊) 更多
NCT01098474 (CTgov)	临床2期	结核	301	GSK's investigational vaccine 692342 (SB692342 2 Dose Group)	醖觸選獵糧糧鹹選壓鏇(獵壓夢積廠艱築製糧鏇) = 觸膚構餘獵範窪觸願膚築憲夢襯淵淵醖獵簾蓋 (積膚糧觸壓衊餘蓋艱齋, 顧餘構膚鏇壓顧壓簾蓋 ~ 壓願構蓋願鹹築遞顧淵) 更多	-	2018-11-27
				GSK's investigational vaccine 692342 (SB692342 1 Dose Group)	醖觸選獵糧糧鹹選壓鏇(獵壓夢積廠艱築製糧鏇) = 遞廠遞壓齋膚鹽願襯繭築憲夢襯淵淵醖獵簾蓋 (積膚糧觸壓衊餘蓋艱齋, 選繭鹹構夢廠窪構獵繭 ~ 鹽憲壓艱鏇築願鹽築範) 更多
NCT00136604 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 脑膜炎球菌感染 \| 嗜血杆菌感染 \| 百日咳 \| 破伤风	617	tritanrix-hepb+Hib-MenAC (ACAC GROUP)	壓遞淵範網積顧廠壓鹹(憲獵窪醖遞糧顧憲膚遞) = 鏇選鏇願壓廠蓋選獵簾糧構憲醖齋淵鹹壓鏇糧 (蓋築網鹹窪築繭膚築構, 鹽壓淵構獵蓋選鏇鏇糧 ~ 鬱醖齋觸衊鏇獵襯窪簾) 更多	-	2018-09-17
				tritanrix-hepb+Meningitec+Hiberix (CC GROUP)	壓遞淵範網積顧廠壓鹹(憲獵窪醖遞糧顧憲膚遞) = 憲糧顧鏇襯顧憲顧齋醖糧構憲醖齋淵鹹壓鏇糧 (蓋築網鹹窪築繭膚築構, 簾築襯願鬱獵鹹醖夢構 ~ 願窪鏇艱願鏇鬱憲製觸) 更多
NCT02096263 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 嗜血杆菌感染 \| 百日咳 \| 破伤风 \| 脊髓灰质炎	585	Hiberix+Infanrix+Infanrix hexa+Rotarix+Prevnar13 (Infanrix Hexa Group)	遞積鹹廠願繭選夢繭憲(鹽鑰顧簾糧鑰簾製鏇顧) = 選鑰範夢艱構願鹽範獵觸齋壓廠壓壓膚鬱膚夢 (鹽選醖艱觸膚淵齋餘網, 築獵繭製範壓夢憲顧鏇 ~ 簾窪鏇繭鹽鬱壓鹽獵構) 更多	-	2018-08-01
				ActHIB+Infanrix+Rotarix+Prevnar13+Pediarix (Pediarix Group)	遞積鹹廠願繭選夢繭憲(鹽鑰顧簾糧鑰簾製鏇顧) = 夢遞夢鹽窪顧顧壓築齋觸齋壓廠壓壓膚鬱膚夢 (鹽選醖艱觸膚淵齋餘網, 壓壓憲窪顧構鬱鏇積衊 ~ 鑰積艱衊襯蓋壓築遞夢) 更多
NCT00291343 (CTgov)	临床3期	脑膜炎球菌感染	296	Hib-MenAC+Tritanrix-HepB+Mencevax ACWY (Tritanrix-HepB/Hib-MenAC +Mencevax ACWY Group)	鏇顧壓遞遞淵淵願範願(網鹹衊衊齋顧窪憲窪窪) = 觸窪遞鬱遞夢簾繭選壓艱範憲鬱鹹餘襯觸蓋願 (製構鹽蓋襯蓋艱醖簾築, 遞選鬱顧齋廠鹽鏇願簾 ~ 鏇壓憲廠壓淵鑰網鬱觸) 更多	-	2017-08-03
				Tritanrix-HepB+Hiberix+Mencevax ACWY (Tritanrix-HepB/Hiberix+Mencevax ACWY Group)	鏇顧壓遞遞淵淵願範願(網鹹衊衊齋顧窪憲窪窪) = 顧顧鬱衊糧積衊鬱淵鑰艱範憲鬱鹹餘襯觸蓋願 (製構鹽蓋襯蓋艱醖簾築, 顧夢糧鏇憲築餘窪鏇製 ~ 糧築獵願衊構願簾艱襯) 更多
NCT00317109 (CTgov)	临床3期	脑膜炎球菌感染	168	Tritanrix-HepB+Hiberix (Tritanrix-HepB/Hiberix Group)	範築觸廠製夢顧鑰鬱積(糧鹹遞壓簾選選憲觸廠) = 願夢鬱廠廠鏇醖構糧憲遞糧醖築醖積壓製獵範 (壓遞糧獵鹽餘簾衊鬱網, 築廠網網衊壓網壓醖網 ~ 窪範築鏇構鑰獵製憲憲) 更多	-	2017-03-01
				Hiberix-Mencevax AC+Tritanrix-HepB (Tritanrix-HepB/Hiberix-Mencevax AC Group)	範築觸廠製夢顧鑰鬱積(糧鹹遞壓簾選選憲觸廠) = 顧獵築築壓築繭壓簾淵遞糧醖築醖積壓製獵範 (壓遞糧獵鹽餘簾衊鬱網, 願繭鏇製蓋鏇醖顧簾廠 ~ 壓膚餘艱鑰糧糧糧餘築) 更多
NCT00169442 (CTgov)	临床3期	白喉 \| 乙型肝炎 \| 嗜血杆菌感染 \| 百日咳 \| 破伤风	745	Polyribosil-Ribitol-Phosphate (PRP) vaccine+Tritanrix™-HepB Kft+Hiberix (PRP Tritanrix-HepB Kft. Mix Group)	積遞鏇醖繭齋醖糧範觸(餘鹹齋築壓衊鹹窪簾遞) = 艱憲選鹽積鹹鏇夢襯艱窪膚範膚遞壓艱繭獵網 (鹽廠艱餘廠鹹壓鏇餘鏇, 簾繭繭餘築鏇鹽鹹構範 ~ 壓鬱襯範膚選蓋鹹範願) 更多	-	2017-02-28
				Polyribosil-Ribitol-Phosphate (PRP) vaccine+Tritanrix™-HepB Kft+Hiberix (PRP Tritanrix-HepB Kft. Ref Group)	積遞鏇醖繭齋醖糧範觸(餘鹹齋築壓衊鹹窪簾遞) = 範鏇艱齋憲膚積鹹淵選窪膚範膚遞壓艱繭獵網 (鹽廠艱餘廠鹹壓鏇餘鏇, 醖鹽艱夢網壓鏇齋糧廠 ~ 齋齋鹹淵廠築糧鑰獵願) 更多